Thomas Lewis
Psychiatry · San Francisco, CANPI 1972654093
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $122,406 of the $134,931 with a category attached, or 90.7%. AbbVie accounts for 62.5% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2023 at $40,083 and has fallen 92.6% since, to $2,961 in 2025. Among psychiatry clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 218 payments — averaging $618.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$84K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$33K
- Teva Pharmaceuticals USA, Inc.$13K
- Takeda Pharmaceuticals U.S.A., Inc.$4K
- Neurocrine Biosciences, Inc.$136
What the payments were for
- Consulting fees$3,7803%
- Speaking & faculty fees$122,40691%
- Travel & lodging$3,6223%
- Food & beverage$5,0774%
- Education$470%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 116 | $84,370 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 43 | $32,755 |
| Teva Pharmaceuticals USA, Inc. | 16 | $13,210 |
| Takeda Pharmaceuticals U.S.A., Inc. | 39 | $4,460 |
| Neurocrine Biosciences, Inc. | 4 | $136 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VRAYLAR$82,463
- CAPLYTA$31,900
- AUSTEDO$13,029
- TRINTELLIX$3,720
How this compares
$134,931 in reported general payments places this provider in the 95th percentile of 4,954 psychiatry providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CaplytaLumateperone Tosylate | 57 | $114,683 |
| TrintellixVortioxetine Hydrobromide | 184 | $95,858 |
| NuplazidPimavanserin Tartrate | 13 | $62,684 |
| RexultiBrexpiprazole | 12 | $34,329 |
| AptiomEslicarbazepine Acetate | 13 | $33,216 |
| VraylarCariprazine Hcl | 27 | $30,489 |
| DayvigoLemborexant | 25 | $12,503 |
| Aimovig AutoinjectorErenumab-Aooe | 11 | $8,309 |
| Galantamine Hbr | 38 | $3,101 |
| SynthroidLevothyroxine Sodium | 52 | $2,693 |
| Dextroamphetamine Sulfate ErDextroamphetamine Sulfate | 12 | $1,795 |
| Zaleplon | 30 | $1,082 |
| Rivastigmine | 12 | $980 |
| Lamotrigine | 60 | $876 |
| Acamprosate Calcium | 12 | $876 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $32,755 | $114,68357 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $4,460 | $95,858184 claims |
| AbbVieVraylar, Synthroid | $84,370 | $33,18379 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,954 psychiatry providers in California.
Other psychiatry in San Francisco
- John KooSan Francisco$3M
- Gustavo AlvaOrange$5.8M
- Jason KelloggIrvine$2.7M
- Jonathan MeyerSan Diego$2.3M
- Charles Tuan-Tu NguyenIrvine$2.1M
- Manoj WaikarLos Gatos$1.9M
- Gerald MaguireSan Juan Capistraco$1.8M
- Salima BrillmanSunnyvale$1.4M
- Bibi DasStanford$1.4M
- Konstantinos TripodisBurbank$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.